| scholarly article | Q13442814 |
| P356 | DOI | 10.1089/10430340460745757 |
| P8608 | Fatcat ID | release_alzcsmlc45e5lod4mw5rkwefzm |
| P698 | PubMed publication ID | 15144573 |
| P2093 | author name string | Mario López Contreras | |
| Ricardo Rosales | |||
| Alberto Tinoco | |||
| Lise Reyes | |||
| Patricia Calzado | |||
| Roberto Posternak | |||
| Tania Navarro | |||
| Carlos Manuel Corona Gutierrez | |||
| Gianni Morosoli | |||
| Mauro Lara Verde | |||
| Roberto Risco Cortes | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cervical intraepithelial neoplasia | Q196788 |
| P304 | page(s) | 421-31 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Human Gene Therapy | Q15757580 |
| P1476 | title | Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus | |
| P478 | volume | 15 |
| Q37118188 | A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting |
| Q46564278 | A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. |
| Q30158017 | A quasi-spontaneous amyloid route in a DNA binding gene regulatory domain: The papillomavirus HPV16 E2 protein |
| Q59329445 | Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus |
| Q38386055 | An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia |
| Q60947009 | Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis |
| Q37579334 | Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis |
| Q36305188 | Chemokine binding protein vCCI attenuates vaccinia virus without affecting the cellular response elicited by immunization with a recombinant vaccinia vector carrying the HPV16 E7 gene |
| Q38092470 | Clinical development of Modified Vaccinia virus Ankara vaccines |
| Q38743922 | Current state in the development of candidate therapeutic HPV vaccines |
| Q37135023 | Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. |
| Q36397581 | Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques |
| Q64260582 | Dietary Polyphenols, Resveratrol and Pterostilbene Exhibit Antitumor Activity on an HPV E6-Positive Cervical Cancer Model: An and Analysis |
| Q33602820 | Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses |
| Q35947683 | Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. |
| Q56967486 | Emerging human papillomavirus vaccines |
| Q36066004 | Emerging human papillomavirus vaccines |
| Q33440600 | Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies |
| Q36018992 | Fighting cancer with vaccinia virus: teaching new tricks to an old dog. |
| Q36532089 | Gene therapy in gynecological cancer |
| Q37581762 | HPV as a model for the development of prophylactic and therapeutic cancer vaccines. |
| Q36480555 | Human papillomavirus infection: an old disease, a new vaccine |
| Q36817148 | Human papillomavirus therapeutic vaccines in head and neck tumors |
| Q38089937 | Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. |
| Q34657561 | Immune therapy for human papillomaviruses-related cancers |
| Q36628376 | Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations |
| Q37703113 | Immunologic treatments for precancerous lesions and uterine cervical cancer |
| Q37545001 | Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein |
| Q34033763 | Immunotherapy for cervical cancer: Research status and clinical potential |
| Q45418101 | Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity |
| Q90863518 | MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis |
| Q37395915 | Medical treatment of cervical intraepithelial neoplasia II, III: an update review |
| Q54937688 | Murine HPV16 E7-expressing transgenic skin effectively emulates the cellular and molecular features of human high-grade squamous intraepithelial lesions. |
| Q84193741 | Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101(+) patients protected mice against chimaeric ecotropic HIV-1 challenge |
| Q30238779 | Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review |
| Q37658876 | Perspectives for the development of human papillomavirus vaccines and immunotherapy |
| Q36541670 | Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma |
| Q33626255 | Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial |
| Q45812304 | Proceedings From the First Asia-Oceania Research Organisation on Genital Infections and Neoplasia (AOGIN) Meeting |
| Q37224926 | Progress and challenges in the vaccine-based treatment of head and neck cancers |
| Q35919119 | Progress in the development of a cervical cancer vaccine. |
| Q42829229 | Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model |
| Q34729962 | Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine |
| Q51820508 | Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. |
| Q35055665 | Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial |
| Q92000123 | Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol |
| Q50052586 | Targeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials |
| Q36384032 | Targeted treatments for cervical cancer: a review. |
| Q40078375 | Targeting Persistent Human Papillomavirus Infection. |
| Q35274806 | Targeting the human papillomavirus E6 and E7 oncogenes through expression of the bovine papillomavirus type 1 E2 protein stimulates cellular motility |
| Q90646281 | The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo |
| Q35805491 | The future of vaccines for cervical cancer |
| Q34077543 | The influence of delivery vectors on HIV vaccine efficacy |
| Q34635024 | The oncogenic potential of human papillomaviruses: a review on the role of host genetics and environmental cofactors |
| Q35826752 | Therapeutic Vaccine Strategies against Human Papillomavirus |
| Q56937332 | Therapeutic human papillomavirus vaccines: current clinical trials and future directions |
| Q36849770 | Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines |
| Q37418916 | Therapeutic vaccines against human papillomavirus and cervical cancer |
| Q38620980 | Use of functional genomics to understand replication deficient poxvirus-host interactions |
| Q34367530 | Using cancer incidence and mortality data to guide cancer control program |
| Q35751946 | Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. |
| Q35925621 | Vaccines against cervical cancer |
| Q38815371 | Virucide properties of cold atmospheric plasma for future clinical applications |
| Q52903256 | [Prophylactic and therapeutic vaccines against human papilloma virus]. |
Search more.